Case Report: Gefitinib in EGFR 19del recurrent aggressive fibromatosis

Case Report: Gefitinib in EGFR 19del recurrent aggressive fibromatosis

We present the first case of a male patient with an epidermal growth factor receptor (EGFR) 19del mutation who was diagnosed with intra-abdominal aggressive fibromatosis and familial adenomatous polyposis. We assessed the clinical response of the patient to first-generation EGFR-tyrosine kinase inhi...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yanjing Guo, Jingjing Wu, Qianming Bai, Juefeng Wan, Qifeng Wang, Xinhong He, Xiaowei Zhang, Zhiguo Luo, Liju Xing, Xin Liu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-07-01
Series:	Frontiers in Oncology
Subjects:	aggressive fibromatosis EGFR 19del targeted therapy gefitinib partial response
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1537714/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Fibromatosis with aggressive demeanor: Benign impersonator of malignancy
by: Naveen Kumar, et al.
Published: (2021-03-01)

Aggressive fibromatosis (desmoid tumor) associated with breast implant: literature review and presentation of three new cases
by: Aloísio Ferreira da Silva Filho, et al.
Published: (2017-09-01)

Fibromatosis Digital Infantil
by: Verónica Molina Vélez, et al.
Published: (1999-11-01)

Gefitinib-induced skin ulceration in metastatic adenocarcinoma lung
by: Vishwanath Sathyanarayanan, et al.
Published: (2014-01-01)

The inhibitory effect of M2 macrophage-derived exosomes on gefitinib resistant lung adenocarcinoma cells through the MIF/TIMP1/CD74 axis
by: Jingcui Peng, et al.
Published: (2025-08-01)

STUDI IN SILICO KOMPLEKS LIGAND-RESEPTOR EUGENOL DAUN BASIL (Ocimum basilicum L.) DENGAN RESEPTOR HER2 PADA NON-SMALL CELL LUNG CANCER (NSCLC) DENGAN KONTROL GEFITINIB
by: Martina Kurnia Rohmah
Published: (2017-09-01)

Berberine protects against gefitinib-induced liver injury by inhibiting the HMGB1/TLR4/NF-κB pathway
by: Qiongyin Zhang, et al.
Published: (2025-08-01)

Pachydermodactyly
by: Reena Kumari Sharma, et al.
Published: (2018-01-01)

Sporadic Right Lumbar Intraabdominal Desmoid Tumor: A Case Report
by: Ong Xin Zen, et al.
Published: (2025-06-01)

Cancer of unknown primary: recent advancements in the diagnosis and treatment
by: ZHAO Ting, ZHANG Xiaowei, LIU Xin, WANG Qifeng, HU Xichun, LUO Zhiguo
Published: (2024-12-01)

High-dose furmonertinib plus bevacizumab in EGFR-mutant non-small cell lung cancer with brain metastases after resistance to third-generation EGFR-TKIs: A retrospective study
by: Yin Pan, et al.
Published: (2025-11-01)

Pyrotinib targeted EGFR/GRP78 mediated cell apoptosis in high EGFR gene copy number gastric cancer
by: Lingbo Bao, et al.
Published: (2025-08-01)

Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer
by: Azhar Ali, et al.
Published: (2018-02-01)

Real-world prognostic factors for first-line EGFR-TKI efficacy in advanced NSCLC patients harboring EGFR 21 L858R mutation
by: Yan’e Liu, et al.
Published: (2025-06-01)

Molecular characteristics and responses to EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients with EGFR exon 19 insertions
by: Yang Li, et al.
Published: (2025-04-01)

The effectiveness of three months EGFR-CTH therapy in palliative colorectal cancer
by: Maciej Pawel Jankowski, et al.
Published: (2025-01-01)

Purine–Hydrazone Scaffolds as Potential Dual EGFR/HER2 Inhibitors
by: Fatemah S. Albalawi, et al.
Published: (2025-07-01)

The Hippo/YAP pathway interacts with EGFR signaling and HPV oncoproteins to regulate cervical cancer progression
by: Chunbo He, et al.
Published: (2015-09-01)

Thematic Analysis of Clinician Documentation Surrounding Treatment Discussions and Decision‐Making in Patients With Desmoid Tumors
by: Victoria Wytiaz, et al.
Published: (2025-08-01)

Surgical Management of Desmoid Tumors—Patient Selection, Timing, and Approach
by: Catherine Sarre Lazcano, et al.
Published: (2025-07-01)

EGFR‐TKIs Induced DPP4 Drives Metabolic Reprogramming of Persister Cells in Lung Cancer
by: Yuanzhou Zhang, et al.
Published: (2025-08-01)

The correlation of HLA-A in Thai EGFR-mutated advanced non-small cell lung cancer, outcome, and tumor microenvironment
by: Nicha Zungsontiporn, et al.
Published: (2025-08-01)

Interleukin 21-Armed EGFR-VHH-CAR-T Cell Therapy for the Treatment of Esophageal Squamous Cell Carcinoma
by: Chenglin Zhang, et al.
Published: (2025-06-01)

An in-depth exploration of four heterogeneity structure-based EGFR mutation subgroups in Chinese non-small cell lung cancer
by: Yongfeng Yu, et al.
Published: (2025-07-01)

De Novo EGFR ‐ALK and EGFR ‐ROS1 Co‐Mutations in NSCLC: Clinical Characteristics, Molecular Profiling, and Treatment Outcomes From a Retrospective Analysis
by: Lili Shen, et al.
Published: (2025-08-01)

Intracellular cholesterol: new functions and therapeutic approaches in NSCLC EGFR-TKI resistance
by: Linjuan Wang, et al.
Published: (2025-07-01)

Efek Mutasi K-RAS pada Kanker Kolorektal terhadap Terapi Antibodi Monoklonal anti EGFR
by: Farid Sastra Nagara, et al.
Published: (2008-12-01)

Cudratricusxanthone A exhibits antitumor activity and enhances chemosensitivity to cisplatin against NSCLC via targeting EGFR
by: Peiyuan Sun, et al.
Published: (2025-08-01)

EGFR polymorphisms drive lung cancer risk and survival disparities: a genotype-expression-outcome cohort study
by: Chao Zuo, et al.
Published: (2025-05-01)

Editorial: EGFR-TKIs for lung cancer treatment: development, application, and side effects
by: Qinglin Shen, et al.
Published: (2025-05-01)

miR‐9 modulates and predicts the response to radiotherapy and EGFR inhibition in HNSCC
by: Francesca Citron, et al.
Published: (2021-06-01)

Advancing EGFR mutation subtypes prediction in NSCLC by combining 3D pretrained ConvNeXt, radiomics, and clinical features
by: Peng Hao, et al.
Published: (2024-11-01)

17β-Estradiol Promotes Tumorigenicity Through an Autocrine AREG/EGFR Loop in ER-α-Positive Breast Cancer Cells
by: Sun Young Yoon, et al.
Published: (2025-05-01)

Hemorrhagic Shock Caused by an Aggressive Fibromatosis in the Gastropancreatic Region: A Case Report
by: Xiufang Yang, et al.
Published: (2025-02-01)

Multimodal prediction of tyrosine kinase inhibitors therapy outcomes in advanced EGFR-mutated NSCLC patients
by: Xiaodong Chai, et al.
Published: (2025-08-01)

MONITORING OF EGFR MUTATIONS IN THE CIRCULATING TUMOR DNA FROM BLOOD PLASMA OF PATIENTS WITH NON-SMALL CELL LUNG CANCER
by: V. A. Shamanin, et al.
Published: (2018-11-01)

miR‐205 mediates adaptive resistance to MET inhibition via ERRFI1 targeting and raised EGFR signaling
by: Cristina Migliore, et al.
Published: (2018-07-01)

The RAS‐related GTPase RHOB confers resistance to EGFR‐tyrosine kinase inhibitors in non‐small‐cell lung cancer via an AKT‐dependent mechanism
by: Olivier Calvayrac, et al.
Published: (2016-12-01)

Triple reversal phenomenon in EGFR-mutant lung adenocarcinoma with prostate metastasis following hepatocellular carcinoma: a rare Case Report with diagnostic and therapeutic implications
by: Jieyan Luo, et al.
Published: (2025-07-01)

Evaluation of the optimal timing of radiotherapy in EGFR-Mutant oligometastatic NSCLC through a retrospective analysis of treatment sequences and survival outcomes
by: Meng Zhang, et al.
Published: (2025-08-01)